{"schema_version":"secwatch.filing_event.v1","accession":"0000105770-22-000050","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.447589+00:00","generated_at":"2026-06-22T23:22:22.069207+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"West Pharma Q3 adj. EPS $2.03; cuts FY2022 guidance; raises dividend 5.6%","bullets":["Net sales $686.9M (-2.8% reported, +4.3% organic); HVP net sales mid-single digit organic growth.","Reported EPS $1.59 (-31.2%); adjusted EPS $2.03 (-1.5%); Biologics and Generics mid-single digit organic growth.","FY2022 guidance cut: net sales $2.830-2.840B (prior $2.950-2.975B), adjusted EPS $8.15-8.20 (prior $9.00-9.15).","Dividend raised 5.6% to $0.19/share, payable Nov 16 to holders of record Nov 9; 30th consecutive annual increase.","Management cited delays in expansion projects and customer mix-shift; expects resolution early 2023; capex guidance lowered to $300-320M."],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-22-000050","json":"https://secwatch.observer/filing/0000105770-22-000050.json","markdown":"https://secwatch.observer/filing/0000105770-22-000050.md","text":"https://secwatch.observer/filing/0000105770-22-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577022000050/0000105770-22-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577022000050/wst-20221027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:22:22.069207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d291f34a82a1dbf515925108bb19098c1a0ed82d","claim":"WEST PHARMACEUTICAL SERVICES INC reported Third-Quarter 2022 results: EPS 2.03.","evidence_excerpt":"(610) 594-3054 Quintin.Lai@westpharma.com Michele.Polinsky@westpharma.com --- EX-99.2 (EX-99.2) --- finalwestq3oct2022 1 Third-Quarter 2022 Third Quarter Overall Net Sales $686.9M | 2.8% Diluted Earnings Per Share: $1.59 Adjusted Diluted Earnings Per Share: $2.03 Eric M. Green President and Chief Executive Officer, Chair of the Board West Pharmaceutical","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577022000050/0000105770-22-000050-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Third-Quarter 2022"},{"label":"EPS","value":"2.03"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d291f34a82a1dbf515925108bb19098c1a0ed82d","claim":"WEST PHARMACEUTICAL SERVICES INC reported Third-Quarter 2022 results: EPS 2.03.","evidence_excerpt":"• Adjusted-diluted EPS of $2.03 declined 1.5%. • Company is updating full-year 2022 net sales guidance to a new range of $2.830 billion to $2.840 billion, compared to a prior range of $2.950 billion to $2.975 billion.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577022000050/0000105770-22-000050-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Third-Quarter 2022"},{"label":"EPS","value":"2.03"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}